Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals is a rare‑disease biopharma focused on IBAT inhibitors. Lead asset LIVMARLI is FDA‑approved for cholestatic pruritus in Alagille syndrome; Volixibat in Phase 2b for cholestasis. Strong pipeline and 2028 revenue drive.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 355
- HQ: Foster City
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.